ASH 2017 | Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib
Constantine Tam
Phase I studies investigating a new monoclonal antibody that works through the inhibition of PD-1 have shown similar levels of efficacy and safety as the current PD-1 inhibitors pembrolizumab and nivolumab, as explained here by Constantine Tam, MD, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, Melbourne, Australia. However, the main area of interest in this drug would be to see its efficacy when combined with a BTK inhibitor, which is currently happening in a Phase Ib study (NCT02795182). This interview was recorded at the American Society of Hematology (ASH) Annual Meeting 2017, held in Atlanta, GA.
Related videos
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
1:28
Potential of CAR T-cells entering the mainstream of cancer treatment
Valentín Ortiz-Maldonado
1:10
Hospital exemption: enabling patients’ access to advanced therapies in the EU
Valentín Ortiz-Maldonado
4:13
Prof. Bader’s highlights from EBMT 2019
Peter Bader
1:31
FMT to treat intestinal dysbiosis in GvHD
Florent Malard
